Abstract
A novel cell line was established from a patient with a leukemic-state nasal angiocentric natural killer (NK) cell lymphoma with systemic skin infiltration. The morphology of the leukemic cells was large-granular-lymphocyte (LGL), and their immunophenotype was CD2+, CD3-, CD5+, CD7+, CD16-, CD56+, and CD57-. The presence of Epstein-Barr viral (EBV) genome was shown in specimens from the patient's nose, skin, and peripheral blood by in situ hybridization using an EBV-encoded small RNA-1 probe or by Southern blotting using a terminal-repeat probe of the EBV genome. Leukemic cells were cocultured with a mouse stromal cell line (SPY3-2) in the presence of 100 U/mL recombinant human interleukin-2 and a novel stromal cell-independent cell line, NK-YS, was established. The NK-YS cells showed LGL morphology and expressed surface CD2, CD5, CD7, CD25, CD56, and CD95. The NK-YS cells retained cytotoxicity against K562 and Jurkat cells. A Southern blotting using a terminal-repeat probe of EBV showed that NK-YS and fresh leukemic cells had a clonal EBV genome, whereas the T-cell receptor beta and gamma chain genes of NK-YS were not rearranged. In an immunocytochemical analysis, the NK-YS cells showed a type-II latent infection of EBV. The NK-YS cells preserved the original characteristics of NK cell lymphoma/leukemia and will be a useful tool for the study of biological characteristics of EBV-associated nasal angiocentric NK cell lymphoma/leukemia.
Copyright 1998 by The American Society of Hematology.
MeSH terms
-
Adult
-
Animals
-
Antigens, CD / analysis
-
Antigens, Neoplasm / analysis
-
Coculture Techniques
-
Cytotoxicity, Immunologic
-
DNA, Viral / analysis
-
Epstein-Barr Virus Nuclear Antigens / biosynthesis
-
Epstein-Barr Virus Nuclear Antigens / genetics
-
Fatal Outcome
-
Female
-
Granuloma, Lethal Midline / pathology
-
Granuloma, Lethal Midline / virology
-
Herpesviridae Infections / pathology*
-
Herpesviridae Infections / virology
-
Herpesvirus 4, Human / isolation & purification*
-
Humans
-
Immunophenotyping
-
In Situ Hybridization
-
Interleukin-2 / pharmacology
-
Killer Cells, Natural / pathology*
-
Killer Cells, Natural / virology
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
-
Leukemia, Lymphocytic, Chronic, B-Cell / virology
-
Lymphomatoid Granulomatosis / pathology*
-
Lymphomatoid Granulomatosis / virology
-
Mice
-
Neoplastic Cells, Circulating / immunology
-
Neoplastic Cells, Circulating / pathology*
-
Nose Neoplasms / pathology*
-
Nose Neoplasms / virology
-
RNA, Messenger / analysis
-
RNA, Viral / analysis
-
Recombinant Proteins / pharmacology
-
Tumor Cells, Cultured* / drug effects
-
Tumor Cells, Cultured* / immunology
-
Tumor Cells, Cultured* / pathology
-
Tumor Cells, Cultured* / virology
-
Tumor Virus Infections / pathology*
-
Tumor Virus Infections / virology
-
Viral Matrix Proteins / biosynthesis
-
Viral Matrix Proteins / genetics
Substances
-
Antigens, CD
-
Antigens, Neoplasm
-
DNA, Viral
-
EBV-associated membrane antigen, Epstein-Barr virus
-
Epstein-Barr Virus Nuclear Antigens
-
Interleukin-2
-
RNA, Messenger
-
RNA, Viral
-
Recombinant Proteins
-
Viral Matrix Proteins